Invention Grant
US08946149B2 Use of exendin and analogs thereof to delay or prevent cardiac remodeling
有权
毒蜥外泌肽及其类似物的使用可延缓或预防心脏重塑
- Patent Title: Use of exendin and analogs thereof to delay or prevent cardiac remodeling
- Patent Title (中): 毒蜥外泌肽及其类似物的使用可延缓或预防心脏重塑
-
Application No.: US11910730Application Date: 2006-04-11
-
Publication No.: US08946149B2Publication Date: 2015-02-03
- Inventor: Christen Anderson , Que Liu
- Applicant: Christen Anderson , Que Liu
- Applicant Address: US CA San Diego US DE Wilmington
- Assignee: Amylin Pharmaceuticals, LLC,AstraZeneca Pharmaceuticals LP
- Current Assignee: Amylin Pharmaceuticals, LLC,AstraZeneca Pharmaceuticals LP
- Current Assignee Address: US CA San Diego US DE Wilmington
- Agency: Womble Carlyle Sandridge & Rice, LLP
- International Application: PCT/US2006/013949 WO 20060411
- International Announcement: WO2006/110887 WO 20061019
- Main IPC: A61K38/26
- IPC: A61K38/26 ; A61P9/10 ; A61K38/22 ; C07K14/605
Abstract:
The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.
Public/Granted literature
- US20090137466A1 Use of GLP-1, Exendin and Agonists Thereof To Delay or Prevent Cardiac Remodeling Public/Granted day:2009-05-28
Information query
IPC分类:
